admin – Page 4101 – Get News Story

Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight

“Thrombocytopenia Drugs Market”

Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.

(Albany, USA) DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of thrombocytopenia, historical and forecasted epidemiology as well as the thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Thrombocytopenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Thrombocytopenia market size from 2020 to 2034, segmented by seven major markets. The Thrombocytopenia Market Report also covers current Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Thrombocytopenia market.

Explore the intricate details of the Thrombocytopenia Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Thrombocytopenia Market Forecast. Click here to stay ahead in healthcare innovation @ Thrombocytopenia Market Size

Key Takeaways from the Thrombocytopenia Market Report

The United States accounts for the largest market size (around 60%) of thrombocytopenia, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Among all cases of thrombocytopenia in the United States, the largest group consists of those with heparin-induced thrombocytopenia followed by chronic liver disease.
DelveInsight’s consultant estimates that the United States accounts for approximately 20% of total cases of Thrombocytopenia in Chronic Liver Disease, in the 7MM.
The United States had the highest cases of thrombotic thrombocytopenia compared to EU4 and the UK and Japan, as assessed in 2023.
The leading Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.
Promising Thrombocytopenia Therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others.
June 2024:- Qidong Gaitianli Medicines Co., Ltd- A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency).
June 2024:- Karyopharm Therapeutics Inc.- A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia. The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
June 2024:- Janssen Research & Development LLC- Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies. The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
June 2024:- Amgen- A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer.
June 2024:- Qilu Pharmaceuticals Ltd- Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia. To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.

Navigate the complexities of the Thrombocytopenia Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Thrombocytopenia Market Forecast. Click here to get more insights @ Thrombocytopenia Treatment Market

Thrombocytopenia Epidemiology Segmentation in the 7MM

Total Thrombocytopenia Cases
Total Cases of Immune Thrombocytopenia
Total Cases of Thrombocytopenia in Chronic Liver Disease
Total Cases of Chemotherapy-induced Thrombocytopenia
Total Number of Cases of Heparin-induced Thrombocytopenia
Total Thrombocytopenia Cases

Delve deep into the Thrombocytopenia Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Thrombocytopenia Market Forecast. Click here to shape the future @ Thrombocytopenia Prevalence

Thrombocytopenia Marketed Drugs

• ADZYNMA: Takeda

ADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant (a disintegrin and metalloproteinase with thrombospondin motifs 13) ADAMTS13 (rADAMTS13) indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA was previously granted Orphan Drug Designation (ODD) by the US FDA for the treatment and prevention of TTP, including its acquired idiopathic and secondary forms, as well as Fast Track and Rare Pediatric Disease Designation. The US FDA also granted Takeda a Rare Pediatric Disease Voucher for the approval of ADZYNMA. ADZYNMA has also been granted ODD by the European Medicines Agency (EMA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of TTP.

• TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis.

Thrombocytopenia Emerging Drugs

• Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma

Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. Rilzabrutinib is currently being evaluated in the Phase III stage of development to treat ITP in adults and adolescents with persistent or chronic ITP. Recently, the LUNA 3 Phase III study showed that rilzabrutinib at a dose of 400 mg twice daily orally successfully met the primary endpoint of achieving a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile observed for rilzabrutinib in this study was consistent with previous findings from other studies.

Unlock insights into the Thrombocytopenia Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Thrombocytopenia Market Forecast. Click here @ Thrombocytopenia Market Drivers and Barriers

Thrombocytopenia Market Insights

Thrombocytopenia is a condition in which the blood has a lower than the normal platelet count. When a patient’s blood has too few platelets, mild to serious bleeding can occur. Bleeding can be internal or underneath the skin, or external. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET,TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Thrombocytopenia Treatment Landscape

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. Danaparoid, argatroban, and lepirudin were approved in the US to treat thrombosis in patients with heparin-induced thrombocytopenia. Current treatment options for severe thrombocytopenia in chronic liver disease include platelet transfusion, splenic artery embolization, splenectomy, and placement of a transjugular intrahepatic portosystemic stent shunt (TIPSS).

Gain a strategic edge in the Thrombocytopenia Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Thrombocytopenia Market Forecast. Click here to lead in advancements @ Thrombocytopenia Clinical Trials Assessment

Scope of the Thrombocytopenia Market Report

Coverage- 7MM
Thrombocytopenia Companies- Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others.
Thrombocytopenia Therapies- VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others.
Thrombocytopenia Market Dynamics: Thrombocytopenia Market drivers and Thrombocytopenia Market Barriers
Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Thrombocytopenia Market Access and Reimbursement

Table of Content

1. Key Insights

2. Report Introduction

3. Thrombocytopenia Market Overview at a Glance

4. Executive Summary of Thrombocytopenia

5. Key events

6. Thrombocytopenia Market Disease Background and Overview

7. Thrombocytopenia Methodology

8. Thrombocytopenia Epidemiology and Patient Population

9. Patient Journey

10. Thrombocytopenia Marketed Products

11. Thrombocytopenia Emerging Therapies

12. Thrombocytopenia Seven Major Market Analysis

13. Market Access and Reimbursement

14. KOL Views

15. Thrombocytopenia Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/pipeline-assessment-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight

ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “ER positive, HER2 negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key ER+/ HER2 -ve Breast Cancer Companies, and future ER+/ HER2 -ve Breast Cancer treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report

Key Takeaways from the ER+/ HER2 -ve Breast Cancer Pipeline Report

In February 2025:- SOLTI Breast Cancer Research Group:- This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole.
In February 2025:- Stemline Therapeutics Inc.;- The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
In February 2025:- AstraZeneca:- This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
In February 2025:- Hoffmann-La Roche:- This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor (ER)-positive, HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting.
In February 2025:- Sermonix Pharmaceuticals Inc.:- This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation.
In February 2025:- Arvinas Estrogen Receptor Inc.:- This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
DelveInsight’s ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment.
The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.
Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others.

Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth ER+/ HER2 -ve Breast Cancer Pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies

ER+/ HER2 -ve Breast Cancer Emerging Drugs Profile

Camizestrant: AstraZeneca

Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant’s ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer.

(Z)-endoxifen: Atossa Therapeutics, Inc.

(Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer.

AC699: Accutar Biotechnology Inc

AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg.

The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment.
ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market.

Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs

ER+/ HER2 -ve Breast Cancer Companies

AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.

ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key ER+/ HER2 -ve Breast Cancer Developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report

Coverage- Global
ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others.
ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others.
ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight’s exclusive ER+/ HER2 -ve Breast Cancer Pipeline Report—access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
ER+/ HER2-VE Breast Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
ER positive, HER2 negative Breast Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Camizestrant: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
(Z)-endoxifen: Atossa Therapeutics, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AC699: Accutar Biotechnology Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
ER+/ HER2-VE Breast Cancer Key Companies
ER+/ HER2-VE Breast Cancer Key Products
ER+/ HER2-VE Breast Cancer- Unmet Needs
ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
ER+/ HER2-VE Breast Cancer Analyst Views
ER+/ HER2-VE Breast Cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-lasers-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Alien UFO Burger Lands in Glasgow

The Out-of-This-World Restaurant Experience Launches on 20th February 2025 – Ready to have your taste buds abducted by flavour? Prepare for an intergalactic dining adventure as Alien UFO Burger, the first ever extra-terrestrial-themed restaurant, opens its doors on 102 Union Street, Glasgow, G1 3QW, on the 20th of February 2025.

Alien UFO Burger promises an out-of-this-world experience with a unique menu that blends cosmic creativity with gourmet quality. Each burger is a universe of its own, meticulously crafted to deliver an explosion of flavors that will leave diners starstruck. From the “Galactic Beef Blaster” to the “Cosmic Veggie Vortex,” there’s something for everyone, whether you’re a meat-lover, vegetarian, or simply curious.

“We’re thrilled to bring something truly unique to Glasgow’s vibrant food scene,” said Solomon, the visionary founder of Alien UFO Burger. “Our mission is to transport our guests to another dimension with every bite. From our immersive space-themed decor to our innovative burger creations, we’re confident that Alien UFO Burger will be a hit with foodies and sci-fi enthusiasts alike.” Upon entering the restaurant, patrons will find themselves in a futuristic setting, complete with glowing alien artifacts, starry walls, and interactive elements that make for an unforgettable dining experience.

The staff, friendly extraterrestrials, are dedicated to providing stellar service. To celebrate the grand opening, Alien UFO Burger will host a special event on launch day. The first 100 visitors will receive an “ALIEN” toy and complimentary Cake Pops. Alien UFO Burger is more than just a place to eat; it’s a destination for anyone looking to escape the ordinary and embark on a culinary journey through the cosmos. Mark your calendars and prepare for lift-off – the countdown to the most anticipated restaurant opening of the year has begun.

Alien UFO Burger will be open to the press, influencers and reporters from the 12th of Feb to the 19th of February 2025.

For more information, please contact:

Name: Solomon Phone: 07300300948

Email: alienufoburger@gmail.com

Alien UFO Burger, Glasgow

Media Contact
Company Name: Alien UFO Burger
Contact Person: Solomon
Email: Send Email
Phone: 07300300948
Country: United Kingdom
Website: https://www.instagram.com/alienufoburger/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alien UFO Burger Lands in Glasgow

Alien UFO Burger Lands in Glasgow Scotland

Upon entering the restaurant, patrons will find themselves in a futuristic setting, complete with glowing alien artifacts, starry walls, and interactive elements that make for an unforgettable dining experience. The staff, friendly extraterrestrials, are dedicated to providing stellar service.

To celebrate the grand opening, Alien UFO Burger will host a special event on launch day. The first 100 visitors will receive an “ALIEN” toy and complimentary Cake Pops.

Alien UFO Burger is more than just a place to eat; it’s a destination for anyone looking to escape the ordinary and embark on a culinary journey through the cosmos. Mark your calendars and prepare for lift-off – the countdown to the most anticipated restaurant opening of the year has begun.

Alien UFO Burger will be open to the press, influencers and reporters from the 12th of Feb to the 19th of February 2025.

For more information, please contact:

Name: Solomon

Phone: 07300300948

Email: alienufoburger@gmail.com

Alien UFO Burger, UK

Media Contact
Company Name: Alien UFO Burger
Contact Person: Solomon
Email: Send Email
Country: United Kingdom
Website: https://www.instagram.com/alienufoburger?igsh=YWhwN3Bra3c5OWxv

New Dog Training Method Takes Salt Lake City by Storm: Dog Trainer Reveals 3-Step Success Formula

Salt Lake City Dog Training Experts Reveal Three Keys to Well-Behaved Dogs

Local Dog Expert Shares Simple Formula Transforming Dogs Across the Wasatch Front

Local dog training experts are transforming the way Salt Lake City pet owners approach dog training with a groundbreaking, simplified method focused on three essential elements: confidence, calmness, and connection.

As Salt Lake City’s dog population continues to grow, many residents struggle with common behavioral issues. This innovative approach to dog training in Salt Lake City addresses everything from basic obedience to complex behavioral challenges through these three fundamental principles.

“Most Salt Lake City dog owners believe good dogs are born that way,” says Ryan Gwilliam, founder and lead trainer at Train Walk Poop. “We’re proving that any dog can become well-behaved through our proven training method, specifically designed for Salt Lake City’s unique urban and outdoor lifestyle.”

The company’s success rate in Salt Lake City dog training has attracted attention from pet owners across the Wasatch Front, from Millcreek to Holladay, demonstrating the effectiveness of their approach in various environments common to Salt Lake City dogs.

Salt Lake City residents interested in transforming their dog’s behavior can learn more about this revolutionary training approach at TrainWalkPoop.com or by calling 801-613-1364.

About Train Walk Poop:

Train Walk Poop is Salt Lake City’s premier dog training service, specializing in training methods that create confident, calm, and connected dogs. Serving the greater Salt Lake City area since 2007.

Contact:

Ryan Gwilliam

Phone: 801-613-1364

Email: info@trainwalkpoop.com

Media Contact
Company Name: Train Walk Poop
Contact Person: Ryan Gwilliam
Email: Send Email
City: South Salt Lake
State: UT
Country: United States
Website: https://www.trainwalkpoop.com

Mondosol Opens Global Platform to Connect with 102-Language Audience

Mondosol, the pioneering multilingual education platform, announces a groundbreaking opportunity for brands to reach an engaged global audience across 102 languages. This strategic move comes as the digital education sector experiences unprecedented growth in cross-border learning experiences.

“The future of education is multilingual, and we’re opening doors for visionary partners,” says Elio Mondello Anza, founder of Mondosol. “Our platform bridges cultural and linguistic gaps, creating unique opportunities for global reach.”

Key Platform Highlights:

1. Unmatched Global Access- Content delivery in 102 languages- Engaged learners across multiple continents- Strategic presence in education, travel, and personal development- Mobile-first audience engagement

2. Premium Content Environment- Expert-curated educational resources- Authentic travel insights from global contributors- Cultural exchange opportunities- Quality-assured multilingual content delivery

3. Strategic Partnership Benefits- Access to a multilingual, education-focused audience- Cross-cultural content distribution- Enhanced global digital presence- Data-driven engagement insights

Partnership Opportunities

Mondosol’s partnership program offers two distinctive collaboration pathways:

1. Featured Publications

– Reach educated, travel

– Enthusiastic audiences

– Professional multilingual content adaptation

– Strategic global positioning

– Cross-cultural audience engagement

2. Strategic Collaborations

– Custom partnership frameworks

– Global content syndication

– Multilingual brand exposure

– Long-term growth opportunities

About Mondosol

Since 2010, Mondosol has been transforming global education and travel experiences. From humble beginnings, the platform has evolved into a trusted name in multilingual education, empowering nearly one million individuals worldwide through authentic learning experiences and cultural insights.

For partnership inquiries or to explore collaboration opportunities, visit Mondosol’s Partnership Portal.

Media Contact
Company Name: Mondosol
Contact Person: Elio Mondello Anza
Email: Send Email
Country: Norway
Website: www.mondosol.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mondosol Opens Global Platform to Connect with 102-Language Audience

Discover the Essence of Sonoma: Halleck Vineyard and Winery’s Intimate Wine Tasting Experience

“Join us at Halleck Vineyard and Winery in Sebastopol, CA for an unforgettable wine tasting journey. Specializing in award-winning wines like Pinot Noir and Chardonnay, we pride ourselves on sustainability and intimate guest experiences. Connect with our winemaker, tour our stunning estate, and delight in exquisite pairings. Secure your exclusive tasting today!”

Experience the charm of Sonoma at Halleck Vineyard, where intimate wine tastings offer a deep dive into award-winning wines like Russian River Pinot Noir, Chardonnay, and Sauvignon Blanc. Nestled in Sebastopol, CA, guests engage with the winemaker, explore sustainable viticulture, and savor curated wine pairings with artisanal delicacies. Limited to small groups, these exclusive estate tours provide a memorable journey into Sonoma’s rich winemaking heritage.

Sebastopol, CA – Halleck Vineyard & Winery, a distinguished winemaker in Sonoma’s world-renowned wine country, invites wine enthusiasts on an intimate journey through its Sebastopol estate winery in West Sonoma County. Known for award-winning Russian River Pinot Noir, Chardonnay, Sauvignon Blanc, White Zinfandel, and Gewurztraminer and a commitment to sustainable viticulture, Halleck Vineyard and Winery offers exclusive wine tastings and estate tours that provide an immersive experience of the art of winemaking and the unique terroir of Sonoma County wines.

A Boutique Wine Tasting Experience Like No Other

Nestled in the Russian River Valley watershed in West Sonoma County, Halleck Vineyard provides guests with an unparalleled opportunity to taste Sonoma Pinot Noir while exploring the vineyard’s breathtaking landscape. Unlike traditional tasting rooms, this estate tour is a deeply personal and exclusive experience, where visitors are welcomed as guests of the family.

“Our philosophy is centered around building community through wine,” says Ross Halleck, founder and winemaker of Halleck Vineyard. “We believe that wine is best enjoyed when shared, and our Sonoma wine tasting experience reflects that sentiment by offering an intimate and educational journey into the heart of Sonoma’s wine making traditions.”

Explore the Distinctive Russian River Valley Pinot Noir Terroir

Sonoma County’s diverse climate and soil conditions make it one of the most sought-after winegrowing regions in the world. At Halleck Vineyard and Winery, guests will gain first-hand insights into the Russian River Valley terroir that produces some of the most exquisite wines in California. The estate-grown Pinot Noir, in particular, benefits from the cooling marine layer of the nearby Pacific Ocean, which allows for a slow, even ripening process that enhances the wine’s complexity and depth.

During the wine tasting, visitors will:

Discover the nuances of Sonoma’s AVAs (American Viticulture Areas) and how they contribute to the unique characteristics of the wines.
Engage with the winemaker and vineyard stewards to understand the craft of small-batch, artisanal winemaking.
Stroll through the estate vineyard independently, seeing sustainable farming practices and the meticulous care given to each vine.

Taste Award-Winning Sonoma Wines

Following the vineyard tour, guests are invited to a guided tasting experience featuring a curated selection of Halleck Vineyard’s acclaimed wines. Each tasting is a journey through the vineyard’s finest selections, paired with artisanal cheeses and local delicacies to elevate the flavors.

The wine tasting experience includes:

Estate-Grown Pinot Noir – A hallmark of Halleck Vineyard, recognized for its layered complexity and elegant structure.
Chardonnay Sobre Vista Vineyard – A crisp and refreshing white wine with balanced acidity and vibrant fruit notes.
Sauvignon Blanc Patient Terrier Vineyard – A bright and aromatic wine that has garnered multiple awards.
Dry Gewürztraminer Calandrelli Vineyard – A unique white wine offering floral and spice-driven aromas.
Dry White Zinfandel – A sophisticated take on a classic varietal, perfect for those who enjoy a lighter-bodied wine.

With each sip, visitors will gain a deeper appreciation for the craftsmanship and dedication that goes into every bottle produced at Halleck Vineyard and Winery.

A Personalized and Intimate Wine Tasting

One of the defining features of Halleck Vineyard’s estate tours is the exclusivity of the experience. Wine tastings are by appointment only, ensuring a relaxed, intimate atmosphere with personalized attention from the vineyard’s team.

Wine Tasting Details:

Reservations Required: By appointment only, to maintain an intimate setting.
Limited Group Sizes: Maximum of 20 guests per tasting, with a premium experience available for groups of 7-12 at $65 per person.
Seating Times: Available Thursday through Sunday at 11:00 AM and 3:00 PM.
Location: 3785 Burnside Rd, Sebastopol, CA 95472.

The Halleck Vineyard Difference: Beyond the Tasting Room

Unlike traditional wineries and tasting rooms, Halleck Vineyard offers a one-of-a-kind experience where guests are invited into the heart of the vineyard. The estate’s inviting and unpretentious setting allows visitors to fully immerse themselves in the winemaking process while connecting with fellow wine lovers.

Halleck Vineyard’s philosophy extends beyond producing exceptional wines; it is about fostering relationships and creating lasting memories. This ethos is reflected in their Inner Circle Wine Club, which grants members exclusive access to rare releases, special events, and personalized allocations.

Book Your Wine Tasting Estate Tour Today

For those seeking an authentic and unforgettable Sonoma wine tasting experience, Halleck Vineyard’s estate tours and tastings offer the perfect blend of education, relaxation, and indulgence. Whether you are a seasoned wine aficionado or new to the world of fine wines, this intimate experience promises to deepen your appreciation for Sonoma’s rich winemaking heritage.

To reserve your estate tour and wine tasting experience, visit Halleck Vineyard or call +1 (925) 726-8306.

About Halleck Vineyard

Halleck Vineyard is an award-winning, family-owned winery located in Sebastopol, CA, specializing in premium Pinot Noir and other fine wines. With a deep commitment to sustainable viticulture and community-building through wine, Halleck Vineyard continues to set the standard for exceptional wine experiences in Sonoma County.

Media Contact: Jennifer Halleck, Halleck Vineyard, Email: jennifer@halleckvineyard.com, Phone: +1 (707) 892-1234

Media Contact
Company Name: Halleck Vineyard Estate Winery & Wine Tasting Room
Contact Person: Jennifer
Email: Send Email
Phone: (707) 892-1234
Address:3785 Burnside Rd
City: Sebastopol
State: California
Country: United States
Website: https://halleckvineyard.com/wine-tasting-sonoma-county/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Discover the Essence of Sonoma: Halleck Vineyard and Winery’s Intimate Wine Tasting Experience

Schizophrenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight

“Schizophrenia Drugs Market”

Schizophrenia companies in the market include Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, among others.

(Albany, USA) DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Schizophrenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Schizophrenia market size from 2020 to 2034, segmented by seven major markets. The Schizophrenia Market Report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Schizophrenia market.

To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast

Some of the key facts of the Schizophrenia Market Report:

The Schizophrenia market size was valued ~USD 7,972 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY™ (xanomeline and trospium chloride), an oral treatment for adult schizophrenia. COBENFY marks the first new class of medication in decades, offering a novel approach by specifically targeting M1 and M4 receptors in the brain, without blocking D2 receptors.
In May 2024, Teva and Medincell reported positive results from the Phase III SOLARIS trial, which evaluated the efficacy of TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injectable for adults with schizophrenia. SOLARIS is a multinational, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use in patients aged 18-65 with schizophrenia.
In March 2024, US-based biopharmaceutical company Acadia Pharmaceuticals announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for treating negative symptoms of schizophrenia failed to meet its primary endpoint. The 26-week, placebo-controlled trial enrolled 454 adult participants with negative symptoms of schizophrenia who had stable control of positive symptoms through ongoing antipsychotic therapy.
The US holds the largest market share for schizophrenia, valued at approximately USD 5,749 million, compared to the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
In 2022, Germany had the largest schizophrenia market size among the EU4 and the UK, at approximately USD 432 million. This market is expected to grow further, with Germany projected to maintain the largest share, followed by the UK, by 2034.
In 2022, Japan’s schizophrenia market was valued at approximately USD 676 million, making it the second largest market. This is expected to grow further by 2034.
According to DelveInsight’s analysis, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022, and this number is expected to rise throughout the study period (2020–2034).
DelveInsight’s analysis estimates that in 2022, the EU4 and the UK accounted for the largest share, approximately 42%, of the total diagnosed prevalent schizophrenia cases in the 7MM. These cases are expected to increase further by 2034.
DelveInsight analysts reported that in 2022, the gender-specific diagnosed prevalent cases of schizophrenia in the US were approximately 757,469 for males and 655,002 for females. These numbers are expected to fluctuate throughout the forecast period (2024-2034).
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
The Schizophrenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Schizophrenia symptoms typically include hallucinations, delusions, disorganized thinking, and impaired cognitive function. Schizophrenia often emerges in late adolescence or early adulthood and can significantly impact daily life and social interactions.

Schizophrenia diagnosis is based on clinical assessments, psychiatric evaluations, and symptom duration. Schizophrenia treatment usually involves a combination of antipsychotic medications, psychotherapy, and social support. Schizophrenia medications, such as second-generation antipsychotics, help manage symptoms but may have side effects.

Schizophrenia causes are not fully understood, but genetic, environmental, and neurochemical factors contribute to its development. Schizophrenia research focuses on understanding brain function, improving treatments, and identifying early intervention strategies. Schizophrenia patients often require long-term care, as the condition can be episodic or continuous.

Schizophrenia burden extends beyond individuals, affecting caregivers and healthcare systems. Schizophrenia awareness and early intervention programs play a crucial role in improving outcomes. Schizophrenia-related stigma remains a challenge, making education and advocacy essential. Schizophrenia management continues to evolve with advancements in neuroscience and personalized medicine, offering hope for better therapeutic approaches in the future.

Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/schizophrenia-market

Schizophrenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Schizophrenia Epidemiology Segmentation:

The Schizophrenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Schizophrenia
Prevalent Cases of Schizophrenia by severity
Gender-specific Prevalence of Schizophrenia
Diagnosed Cases of Episodic and Chronic Schizophrenia

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast

Schizophrenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Schizophrenia Therapies and Key Companies

RP5063 (brilaroxazine): Reviva Pharmaceuticals
MIN-101 (roluperidone): Minerva Neurosciences
KarXT (xanomeline-trospium): Karuna Therapeutics
NUPLAZID (pimavanserin): Acadia Pharmaceuticals
ICELPERTIN (BI-425809): Boehringer Ingelheim
SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical
OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi
LYN-005: Lyndra Therapeutics
NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals
CVL-231 (emraclidine): Cerevel Therapeutics
Seroquel Sustained Release: AstraZeneca
Intramuscular Olanzapine Depot: Eli Lilly and Company
Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics
NBI-1117568: Neurocrine Biosciences

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

Schizophrenia Market Drivers

Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.

Schizophrenia Market Barriers

WHO’s Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.

Scope of the Schizophrenia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies
Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2020–2034)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17. Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight

Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Recurrent Ovarian Cancer Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Advanced Recurrent Ovarian Cancer Pipeline Report to explore emerging therapies, key Advanced Recurrent Ovarian Cancer Companies, and future Advanced Recurrent Ovarian Cancer treatment landscapes @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

In February 2025:- Mayo Clinic– This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States.
DelveInsight’s Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
The leading Advanced Recurrent Ovarian Cancer Companies such as IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.

Discover how the Advanced Recurrent Ovarian Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Advanced Recurrent Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Recurrent Ovarian Cancer Clinical Trials and Studies

Advanced Recurrent Ovarian Cancer Emerging Drugs

Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S’ ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.

ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C’Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001’s high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

The Advanced Recurrent Ovarian Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.

Get a detailed analysis of the latest innovations in the Advanced Recurrent Ovarian Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Advanced Recurrent Ovarian Cancer Unmet Needs

Advanced Recurrent Ovarian Cancer Companies

IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Advanced Recurrent Ovarian Cancer Therapies and key Advanced Recurrent Ovarian Cancer Developments @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

Coverage- Global
Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.
Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Advanced Recurrent Ovarian Cancer drug development? Find out in DelveInsight’s exclusive Advanced Recurrent Ovarian Cancer Pipeline Report—access it now! @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Advanced Recurrent Ovarian Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company Name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Maveropepimut S: IMV
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Advanced Recurrent Ovarian Cancer Key Companies
Advanced Recurrent Ovarian Cancer Key Products
Advanced Recurrent Ovarian Cancer- Unmet Needs
Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
Advanced Recurrent Ovarian Cancer Analyst Views
Advanced Recurrent Ovarian Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Cornmi NeoVista X7 Is Now Live on Indiegogo

We are thrilled to announce the launch of the CORNMI NeoVista X7 Lite, now live on Indiegogo! This groundbreaking device is set to redefine your visual experience with its stunning 62° FOV, 45 PPD, and 1080P high-definition display, ultra-lightweight design, and sleek, modern aesthetics. Whether you’re a tech enthusiast, a gamer, or someone who appreciates premium design, the NeoVista X7 Lite is here to impress.

Visit our Indiegogo page now to learn more and secure your device at an exclusive early-bird price:https://igg.me/at/cornmi-x7lite/x/38364133

Unmatched Visual Clarity

The NeoVista X7 Lite delivers 1080P high-definition visuals with a 62° field of view (FOV) and 45 pixels per degree (PPD), ensuring every detail is crisp and vibrant. With its advanced display technology, you’ll feel fully immersed in your favorite games, movies, or virtual experiences. The stunning clarity and vibrant colors make it a must-have for anyone seeking a superior visual experience.

Designed for Comfort and Style

Weighing in at an incredibly light weight of just 228g, the NeoVista X7 Lite is crafted for all-day comfort. Its ergonomic design and balanced weight distribution ensure that you can enjoy extended use without discomfort. Plus, its sleek, modern design makes it a stylish addition to any setup, perfect for those who value both form and function.

Early-Bird Special: Save 36%!

For a limited time, we’re offering an exclusive 36% discount for early backers on Indiegogo. This is your chance to be one of the first to experience the NeoVista X7 Lite at an unbeatable price. Don’t miss this incredible opportunity to upgrade your tech collection.

Visit our Indiegogo page now https://igg.me/at/cornmi-x7lite/x/38364133

Why Wait? Join the Revolution Today!

The CORNMI NeoVista X7 Lite is more than just a device—it’s a gateway to a new dimension of visual excellence. With its groundbreaking technology, elegant design, and unbeatable early-bird pricing, there’s never been a better time to elevate your viewing experience.

Media Contact
Company Name: CORNMI INTERNATIONAL
Contact Person: Media Manager
Email: Send Email
Country: United States
Website: https://igg.me/at/cornmi-x7lite/x/38364133